Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 5, Issue 1 (2016)

Acute myocardial infarction with St-segment elevation: effect of myocardial revascularization, Atorvastatin, Bisoprolol, perindopril and antiplatelet drugs on heart remodeling, systolic and diastolic dysfunction and cardiac complications over the period of 24.3 months

Author(s):
Denesiuk OV
Abstract:
28 male patients aged 42-65 years with AMI with ST-segment elevation being treated at the infarction department of Vinnytsia city hospital No1 from 2007 to 2014 were studied. AMI with comorbid arterial hypertension occurred in 23 patients (82.1%). Troponin 1contents, blood lipids, ECG, M- and B-mode echocardiography data were studied to control the effect of treatment; coronary angiography was done using Siemens Axiom Sensis XP (Germany) unit. In male patients with AMI and elevation of STsegment before treatment there was domination in eccentric type of LVH; tendency to the development of III (severe) degree and II (moderate) degree of LV dilation; I and II degrees of left atrium dilationindicating the development of heart remodeling. Impaired systolic function was not common, and predominant type of diastolic dysfunction was delayed relaxation. After CA stenting and further treatment with atorvastatin, bisoprolol, perindopril and ASA in optimal doses over the period of 24.3 months (clopidogrel was administered only for 3 months) there was decrease of LVH types, left atrium dilation, systolic and diastolic dysfunction indicating the regression of heart remodeling which had positive effect on clinical course of disease. However, there was progressive increase in angina attacks, cardiac failure, and one case of nonfatal MI.
Pages: 39-42  |  1768 Views  83 Downloads


The Pharma Innovation Journal
How to cite this article:
Denesiuk OV. Acute myocardial infarction with St-segment elevation: effect of myocardial revascularization, Atorvastatin, Bisoprolol, perindopril and antiplatelet drugs on heart remodeling, systolic and diastolic dysfunction and cardiac complications over the period of 24.3 months. Pharma Innovation 2016;5(1):39-42.

Call for book chapter